Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
I will look at those companies PWA as always interested in diversification opportunities. If you sold for 16p and were in at 6p you have made a 167% return. If you were running an investment fund with that kind of return, every man and his dog would sign up (the banks pay nothing on savings). You have done well with TEK!
There are no guarantees with start ups but I am very happy with the progress TEK are making and happy to play the long game on this particular share due to their enormous potential. Ultimately it will be worth it.
Fair play PWA, glad you made some profit and hope your alternative investment choices do the business for you.
Everybody has their own perspective. Personally, if I think if you remove frustration (regarding timings) and think dispassionately , this is a company moving in the right direction (on multiple fronts in large markets) and I am convinced the potential for exciting returns exists. We shall see!
Have a good weekend all.
Giancotti, which small cap technology firms are not based on speculation?
If TEK was an established player (with an established revenue stream) we would not be at 16.5p. While entirely correct, the current SP and the speculative nature of TEK go hand in hand.
The market that Guident is attempting to operate in (its core business is autonomous vehicles) is not fully established yet. So very hard not to be speculative in nature when operating in an immature market. The story of guident (shock absorbers aside) will develop over years.
TEK is attempting to penetrate large markets with some impressive IP assets.
I appreciate NDAs mean nothing in themselves and may not come to fruition. We all do.
.1% - On that basis you have assigned the regenerative shocks absorbers a 1 in 1000 chance of uptake? Given that two players have started testing the technology, so quickly after TEK acquired the IP, I am more optimistic than 1 in 1000. But, realistic that success may not come immediately on this front. It is also possible that Guident will enhance the regenerative shock absorbers technology over time (even if they are not taken up now).
But, if any event, regenerative shock absorbers are not the core business for Guident. They are an exciting bonus.
TEK are knocking on the door in various different spaces. While it is entirely possible for a small cap SP to be based entirely on speculation, TEK actually should be producing some concrete numbers on Salarius and Lucyd…..which should help investors assess the progress objectively.
Nobody can give you a cast iron guarantee of clearance. Based on the statement from Bellucura on the 3rd of December there is every reason to be hopeful regarding imminent clearance (depending on level of trust you assign to the CEO).
Robert Rauker, CEO of Belluscura commented:
"Whilst we do not have a specific timetable, we have been told by the FDA that, as a COVID-19 treatment, the device will be given priority review and we are hopeful that FDA clearance will be granted this year."
TEk in my opinion have earned some degree of investor trust through successfully bringing Salarius and Lucyd from concept to market. This gives me reason to think TEK's management oversight will also bring belluscura to market.
Guident is also more advanced at this stage relative to expectation (with the exciting regenerative shock absorbers coming out of now where - not representing core business).
Last week there was some profit taking. Fair enough. Additionally, the markets in general are not adverse to shaking the tree to see who falls out. Based on the currently available information, long term investors should hold on to their golden tickets IMO.
GLA
I had to have a strong word with myself when it was under 9p a few weeks back, a side of me wanted to flog the house and stick it on TEK ;)
The market is still slightly underwhelmed/ unconvinced by TEK. But, if belluscura gets FDA approval (seemingly a high chance of imminent clearance), i would expect to a SP north of 20p.
Seems a very reasonable risk v reward to me.
GLA
Too busy at work to write one of my tiresome war & peace length commentaries .
But, hugely positive news . In a year of impressive progress and exciting surprises (regenerative shock absorbers !!).
Thanks for your hard work TEK! Time to push on with these exciting portfolios.
This stock is undervalued.
GLA
Agree with you topcatz.
Would nice to have a clearer understanding of what is going on under the bonnet , especially with regard to FDA Approval.
But based primarily on my instincts regarding salarius and general progression of portfolios (fingers crossed for FDA approval ) have just topped up again .
Good luck everybody
Cheers Adamsky, always welcome your perspective.
I emailed Tim at flagstaff on Wednesday relaying the sentiment among investors that an update is due on FDA Clearance. No response as yet. Let’s hope positive news is imminent.
All the best
AIM market statistically speaking is dominated by failure and not success.
My subjective assessment is the direction of traffic at TEK at the moment is pointing towards success. Which if achieved would make TEK one of the exceptions on AIM and not the rule. The SP reflects the very real dangers/ uncertainty that exist for all start ups. I am more bullish than the market because I think on the balance of probabilities the SP should be higher currently.
TEK not only has the potential to penetrate one of these large markets but has made concrete steps in this journey in the past 12 months. Either through steady progress (the salarius distribution network) or with a transformative big deal down the line success looks more probable now than previously. This is what I judge TEK on. It’s going in the right direction in a precarious environment.
Have a great weekend Adamsky/everybody and good luck!
(this posted in a weird order...this was the last of three posts)
TEK has responsibilities in terms of investor information and I don’t think there is any question that it has adhered correctly to these responsibilities. In terms of additional information above these responsibilities, there is a balance between transparency and creating un-necessary/disproportionate movements in the SP by releasing information that is hard to contextualise (as we are not scientists/developers).
Missing FDA clearance and delayed market release is not in itself any evidence of mismanagement. There is always an element of "how long is a piece of string” in any development project. That is the reality. For me, some of the posts in this forum conjure the image of us as investors, sat in the back seat of the car not knowing/understanding the route, saying to the beleaguered technicians/scientists saying “are we there yet?” We as investors (or certainly most of us) do not have an appreciation of the complexities involved in advancing the multitude of patents to fruition (i.e. an FDA approved product). That doesn’t mean that the question should not be asked, just that the fact that we are not there yet, is not evidence of failure.
I am also conscious that Belluscura will be operating in a competitive environement, so the TEK offering has to be sufficiently distinct to penetrate this market. If Belluscura can offer such a product in 2020 or frankly at any point in the future, it is not priced in to the current SP and would represent a massive win for investors.
The fact that TEK has got Lucyd and Salarius to market increases the probability (for me) that they will get Belluscura over the line too. It demonstrates that TEK are not just about concepts but also results. To a lesser extent Guident also appears advanced relative to where many thought it would be at this stage. Making Belluscura the outlier in the portfolio. This gives me some confidence, in the inherently uncertain world of AIM start ups that Belluscura is receiving the right management oversight and support.
In these strange times, it is also worth remembering that COVID will have impacted all the portfolios. Supply chains and increased working from home will affect business and development.
Hi Adamsky,
Thanks for your comments. We are all want TEK to be successful and I am always interested in your perspective even if our view is not fully aligned.
I will give my thoughts on your view and will be direct but please don't interpret that as me saying you are wrong. I certainly don't think you are wrong, I just think there are a lot of unknowns and given the unknowns it is natural for investors to form different opinions. Plus, I like hearing your and other views on the board as I am excited about TEK.
High level. The AIM market has been littered with failures. The odds when investing in AIM are stacked against us all. That is the statistical reality of this investment market. Investing in AIM is inherently risky and there is a very real (in fact statistically likely chance) that we could lose our entire investment based on the small number of successes relative to failures.
Given that back drop, I am hugely impressed that Lucyd and Salarius are now commercially viable propositions.
In short, while it is impossible for anybody to know for sure, I think Salarius can pay the bills. That is huge because that is my number one concern, not losing my full investment. As was noted, our Salarius CEO was bullish about the ability to scale up production (apparently the latent capacity is there) and spoke about the learning curve with regard to the mass production of the micro salt. There is a huge difference between a patent for micro salt and an actual offering available to market. Salarius is now linked to major distributors and I believe "take off" is now possible (if we have assessed the potential of the product correctly). I am genuinely excited for this product and I think we all should recognise the huge progress they TEK made in the last year.
You are frustrated by CEO Victor Manzanilla’s side line in writing books and “preaching”. I am totally indifferent to his side line. My interest in him is entirely limited to his representation of Salarius. So as long as his side line produces no negative associations with Salarius, I am completely un concerned by his other activities. In fact, if he is doing a good job (I do not have the information to judge) we want him to be happy and engaged as we will retain his services for longer. If he has a large profile/following this could potentially help not hinder Salarius. I suspect, you are not too impressed by his subject material. It is not for me either. But, as long as there are no negative associations that reflect on Salarius, he can fill his boots in my view.
I don't agree there is evidence of mismanagement at Belluscura. I don't feel we don't have the information to ascertain this (we don't have the full picutre). Progress has not been transparent that is fair. As I noted below, we need an update to as to progress (or lack of it).
Thanks for your thoughts as always !
My view is very simple. TEK is a start up that has made huge progress this year and success awaits for the patient.
It has progressed Lucyd and salarius from concept to commercial reality . There is a lot of criticism and frustration on this board but both these portfolios are now where they need to be .
They will either succeed (or not) based on the merits of the offering.
If salarius is not a success then it will not be down to mismanagement by TEK as the product is linked to major suppliers and has all the exposure it requires for take off. My belief backed by heavy investment is that a market exists for this product and it alone is worth a multiple of the market cap.
I will wait it out. If I am wrong , I will take it on the chin but TEK have done a great job this year with Salarius . Now we wait to see if we have all judged the potential of this product correctly. Forget your analysis of the accounts, it all comes down to demand for the product! We shall see. I am confident.
Lucyd: I hope a bigger player buys the technology but will happily be proved wrong if TEK can produce some decent sales numbers.
Belluscura: TEK simply have to give an update as to the progress ( or lack of it) this year. If FDA clearance is not achieved in 2020 we are owed an explanation. For me, i would still keep my investment in TEK based on the combined value of the other portfolios but I want honest communication from the board. I also believe they will get it over the line .....eventually
Guident: automotous flying drones are well over my head ;) but the technology must have considerable value. What’s going on with the regenerative shock absorbers ?? Could be hugely marketable.
It’s a tiny market cap....I believe the salt will make big returns on its own. Hence , in terms of my investment I can afford to view the other portfolios as exciting bolt ons - but they are bolts on that could exceed all expectations!!
I am in for the long term and not losing any sleep about the current SP (it could shift dramatically very quickly).
It’s a start up. Fortune favours the brave but also the patient when it comes to start ups.
Good luck all
Thanks for the post TopCat. The Lucyd light glasses look really good! An improved offering which can only be a positive thing.
I am with you, yet to be convinced by Lucyd but will very happily be proved wrong!!!! One concern is I am aware Bose sell audio glasses (that are wireless and interact with your phone's voice assistant). I don't know how the Lucyd offering compares in terms of quality (not an expert in the technology) but it is hard to compete against these giants (which have a marketing advantage) unless you have a very distinct product. I don't know if the Bose offer prescription lenses (Lucy does offer this).
If Lucyd develops this IP perhaps they can sell it to a bigger player. Hoping Lucyd a success obviously.
Overall, really impressed with TEK's direction of travel at the moment. Plenty of value at this share price. I tip my hat to the board on the progress made and if they get Belluscura over the line I will put my dancing shoes on!!!!
Good luck all
TEK is still in real terms in it’s infancy as a company. But, it has a fantastic team in place, business model and is making concrete progress.
Guident - Really positive developments in terms of the strategic alliance with Bestmile. It is one thing winning prizes for the technology but this will demonstrate the application (and commercial value) in the real world. Quite taken back but intrigued by the regenerative shock absorbers. If TEK can commercialise this IP as well then the potential revenue stream is exciting.
Salarius - again , a very positive deal with an established distributor . As correctly pointed out this will give salarius great exposure. It may not be the Mega deal that sends the SP rocketing but it may well prove to be a pivotal moment in the company’s development .
Belluscura - We all want success yesterday. I accept that the delays have never been fully explained to investors. But, if FDA approval is in 2020 (hopefully!!) or 2021 , if TEK releases a marketing leading product (in what is a huge market for COPD and other conditions) I will be thrilled as it is not factored into the current SP. The proposed offering is a far cry from a crude oxygen pump as was suggested (perhaps in jest). The top of the range concentrators go for £2k and TEK’s proposed offering has many new features and patented attributes (though TEK is looking to make a comparatively cheaper model - not expecting to sell near £2k ).
Lucyd - who knows , might surprise us !!
TEKFOOD - could be an earner ...
TEK is assessing new technology all the time , with access to institutions globally - what a business model !!
Each to their own in terms of investment strategy but personally.....
I would not pay too much attention to the current SP. 30% corrections just demonstrate that the market still don’t have a firm handle on the value of the IP.
I also would not trade the volatility on this stock.....as TEK has the potential to produce a truly transformative RNS (this is a stock to hold on to)
This is a company on a journey with massive potential- Good luck all
In this context “surety check “ sounds like just part of the interactive review process. Not surety in the traditional financial meaning .
It is not my field of expertise . But the 510k process is interactive. Not an immediate straight pass or fail . The applicant (TEK) has a time period to address/rectify issues flagged by the FDA. If the applicant can resolve highlighted issues within a defined period then approval can still be gained . If they can’t be corrected in the required time frame the 510k will be failed and the applicant will have to submit a separate 510k application.
It is worth noting , that the whole essence of 510k process , is that the product does not represent a new piece of technology - rather an improved version of pre-existing technology. So TEK are not reinventing the wheel.
Belluscura have a high probability of bringing this concentrator to market IMO. This is not fully priced into the SP (and obviously TEK has more than one string to it’s bow). Good times await with patience .
GLA